The U.S. Centers for Medicare and Medicaid ruled after the close Thursday that it will fully cover Dendreon Corp.'s (DNDN) Provenge, a treatment for advanced prostate cancer. The stock is now trading higher by 0.91 on 443K shares.
Dendreon Corp. gapped up at the open Thursday, but steadily declined during the first hour of trade. The stock finished down by 1.06 at $39.44 on above average volume.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.